NSE · Healthcare · Biotechnology
EPS came in at 5.52 against a street estimate of 5.60 — a miss of 1.4%.
with an average price target of ₹1,550.60.
CONFIDENT Concord delivered 26% YoY revenue growth in Q1 FY'27 to ₹257cr, driven by broad-based API strength (+46% exports) and new product launches. EBITDA margin expanded 190bps to 32%. Management targets ₹3,000cr revenue in 5–6 years without major capex. Q1 FY'27 Exports broad-based across Europe, Japan, LatAm. Domestic formulation headwind from Middle East tender loss (prior year large contributor). Injectable exports expected post-12–15 month regulatory approval timelines. Analysts pressed on growth composition (normalization vs. structural), capacity utilization path to ₹3,000cr, and injectable facility ramp timing. Management confirmed broad-based growth, delayed injectable externalization to H2, and capacity headroom until 80–85% utilization triggers expansion. 2026-08-03…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call CONCORD BIOTECH LIMITED – Q1 FY27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Q1 FY27 Total Revenue: INR 257 crores – 26.2% year-on-year growth (vs INR | 2026-08-07 |
| Annual report FY2026 CONCORD BIOTECH LIMITED – ANNUAL REPORT FY2025-26 SUMMARY --- HEADLINE NUMBERS • Revenue from operations FY26: ₹1,054.9 crore (compared to ₹1,200.1 | 2026-07-07 |
| Q4 FY26 earnings call CONCORD BIOTECH LIMITED – FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue (FY26): INR 1,049 crores, down 12% year-on-year • Q4 FY26 Revenue: Down 2 | 2026-06-05 |
| Investor presentation · Q4 FY26 CONCORD BIOTECH LIMITED – INVESTOR SUMMARY Financial Year Ended March 31, 2026 --- HEADLINE NUMBERS • FY26 Revenue: Rs 1,054.9 Crores (down 12% YoY | 2026-05-30 |
| Quarterly results · Q4 FY26 CONCORD BIOTECH LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Full Year Revenue from Operations (FY 2025-26): Rs. 1,05,507.10 lakhs (vs. Rs. 1,20,00 | 2026-05-30 |
| Q3 FY26 earnings call CONCORD BIOTECH LIMITED - Q3 & 9 MONTHS FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 278 crores (14% YoY growth vs INR 244 crores in Q3 FY25 | 2026-02-18 |
| Quarterly results · Q3 FY26 CONCORD BIOTECH LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Board meeting held on February 11, 2026 to approve Q3 FY2025-26 (quarter ended Decembe | 2026-02-11 |
| Investor presentation CONCORD BIOTECH LIMITED – INVESTOR SUMMARY Q3 & 9 MONTHS FY26 (ENDED DECEMBER 31, 2025) --- HEADLINE NUMBERS • Q3FY26 Revenue: Rs 277.8 crores (up | 2026-02-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹7.55 / share ex-date Jul 24, 2026 | 2026-07-24 |
| Dividend | ₹10.70 / share ex-date Sep 3, 2025 | 2025-09-03 |
| Announcement | Date |
|---|---|
| Acquisition of another business entity announced Concord Biotech Limited has informed the Exchange about Acquisition | 2026-06-20 |
| Acquisition announced by the company Concord Biotech Limited has informed the Exchange about Acquisition | 2026-04-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Concord Biotech Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.